CY1119805T1 - Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων - Google Patents
Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιωνInfo
- Publication number
- CY1119805T1 CY1119805T1 CY20171101264T CY171101264T CY1119805T1 CY 1119805 T1 CY1119805 T1 CY 1119805T1 CY 20171101264 T CY20171101264 T CY 20171101264T CY 171101264 T CY171101264 T CY 171101264T CY 1119805 T1 CY1119805 T1 CY 1119805T1
- Authority
- CY
- Cyprus
- Prior art keywords
- administration
- delivery system
- drug delivery
- aquatically
- absolute
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 230000002452 interceptive effect Effects 0.000 title 1
- 238000012377 drug delivery Methods 0.000 abstract 5
- 239000002245 particle Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009826 distribution Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE2007/001127 WO2009078754A1 (en) | 2007-12-19 | 2007-12-19 | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| PCT/SE2008/051515 WO2009078802A1 (en) | 2007-12-19 | 2008-12-18 | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119805T1 true CY1119805T1 (el) | 2018-06-27 |
Family
ID=40795732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101264T CY1119805T1 (el) | 2007-12-19 | 2017-12-04 | Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων |
| CY2019021C CY2019021I1 (el) | 2007-12-19 | 2019-04-24 | Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2019021C CY2019021I1 (el) | 2007-12-19 | 2019-04-24 | Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8999382B2 (https=) |
| EP (1) | EP2231189B1 (https=) |
| JP (1) | JP5466172B2 (https=) |
| KR (1) | KR101572703B1 (https=) |
| CN (1) | CN101951956B (https=) |
| AU (1) | AU2008339099B2 (https=) |
| BR (1) | BRPI0821740B1 (https=) |
| CA (1) | CA2709266C (https=) |
| CY (2) | CY1119805T1 (https=) |
| DK (1) | DK2231189T3 (https=) |
| EA (1) | EA015247B1 (https=) |
| ES (1) | ES2650242T3 (https=) |
| FR (1) | FR19C1030I1 (https=) |
| HR (1) | HRP20171796T1 (https=) |
| HU (1) | HUE034684T2 (https=) |
| LT (2) | LT2231189T (https=) |
| LU (1) | LUC00117I2 (https=) |
| MX (1) | MX2010006914A (https=) |
| MY (2) | MY157187A (https=) |
| NL (1) | NL300987I9 (https=) |
| NO (2) | NO2231189T3 (https=) |
| NZ (1) | NZ586859A (https=) |
| PL (1) | PL2231189T3 (https=) |
| PT (1) | PT2231189T (https=) |
| SI (1) | SI2231189T1 (https=) |
| WO (2) | WO2009078754A1 (https=) |
| ZA (1) | ZA201004685B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078755A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078754A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| KR20120022984A (ko) * | 2009-04-21 | 2012-03-12 | 셀렉타 바이오사이언시즈, 인크. | Ｔｈ１ 편향 반응을 제공하는 면역나노치료법 |
| AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| CN103908432B (zh) * | 2013-01-02 | 2018-09-21 | 博瑞生物医药（苏州）股份有限公司 | 一种伊沙匹隆白蛋白的冻干组合物及其制备方法 |
| CN112321465B (zh) | 2019-07-18 | 2023-06-06 | 上海现代药物制剂工程研究中心有限公司 | 一种含苯基化合物、其中间体、制备方法及应用 |
| CN112239418B (zh) * | 2019-07-18 | 2023-07-07 | 上海现代药物制剂工程研究中心有限公司 | 视黄醇类化合物及其钠盐的制备方法 |
| WO2021259472A1 (en) * | 2020-06-24 | 2021-12-30 | Oasmia Pharmaceutical Ab | Micellar docetaxel for use in the treatment of cancer |
| CN115429886B (zh) * | 2021-06-02 | 2025-10-31 | 复旦大学 | 一种药物纳米结晶制剂及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| US6197809B1 (en) * | 1998-12-23 | 2001-03-06 | Ardenia Investments Ltd. | Compounds for the treatment of cancer |
| US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| SE0101702D0 (sv) * | 2001-05-15 | 2001-05-15 | Ardenia Investments Ltd | Novel potentiating compounds |
| US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
| US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| EP1534672B1 (en) * | 2002-07-23 | 2013-05-01 | Ardenia Investments Ltd. | Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents |
| SE0202311D0 (sv) * | 2002-07-23 | 2002-07-23 | Ardenia Investments Ltd | Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment |
| US7259984B2 (en) * | 2002-11-26 | 2007-08-21 | Cornell Research Foundation, Inc. | Multibit metal nanocrystal memories and fabrication |
| JP2006199590A (ja) | 2003-09-04 | 2006-08-03 | Nano Career Kk | 水溶性の塩基性薬物内包ナノ粒子含有組成物 |
| WO2005089106A2 (en) | 2004-02-27 | 2005-09-29 | Molecular Therapeutics, Inc. | Degradable nanoparticles |
| US7871632B2 (en) | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
| US8945629B2 (en) * | 2004-09-10 | 2015-02-03 | University Of Wyoming | Nanoparticles for cytoplasmic drug delivery to cancer cells |
| AU2006284657B2 (en) * | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078755A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078754A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
-
2007
- 2007-12-19 WO PCT/SE2007/001127 patent/WO2009078754A1/en not_active Ceased
-
2008
- 2008-12-18 WO PCT/SE2008/051515 patent/WO2009078802A1/en not_active Ceased
- 2008-12-18 BR BRPI0821740-8A patent/BRPI0821740B1/pt active IP Right Grant
- 2008-12-18 NZ NZ586859A patent/NZ586859A/en unknown
- 2008-12-18 LT LTEP08861526.5T patent/LT2231189T/lt unknown
- 2008-12-18 PL PL08861526T patent/PL2231189T3/pl unknown
- 2008-12-18 KR KR1020107015610A patent/KR101572703B1/ko active Active
- 2008-12-18 EP EP08861526.5A patent/EP2231189B1/en active Active
- 2008-12-18 EA EA200802350A patent/EA015247B1/ru unknown
- 2008-12-18 SI SI200831891T patent/SI2231189T1/en unknown
- 2008-12-18 CN CN2008801270180A patent/CN101951956B/zh active Active
- 2008-12-18 MY MYPI2010002786A patent/MY157187A/en unknown
- 2008-12-18 JP JP2010539385A patent/JP5466172B2/ja active Active
- 2008-12-18 AU AU2008339099A patent/AU2008339099B2/en active Active
- 2008-12-18 HU HUE08861526A patent/HUE034684T2/en unknown
- 2008-12-18 US US12/809,252 patent/US8999382B2/en active Active
- 2008-12-18 MY MYPI2010002787A patent/MY157186A/en unknown
- 2008-12-18 CA CA2709266A patent/CA2709266C/en active Active
- 2008-12-18 PT PT88615265T patent/PT2231189T/pt unknown
- 2008-12-18 HR HRP20171796TT patent/HRP20171796T1/hr unknown
- 2008-12-18 MX MX2010006914A patent/MX2010006914A/es active IP Right Grant
- 2008-12-18 ES ES08861526.5T patent/ES2650242T3/es active Active
- 2008-12-18 NO NO08861526A patent/NO2231189T3/no unknown
- 2008-12-18 DK DK08861526.5T patent/DK2231189T3/en active
-
2010
- 2010-07-02 ZA ZA2010/04685A patent/ZA201004685B/en unknown
-
2015
- 2015-02-27 US US14/633,177 patent/US9993438B2/en not_active Ceased
-
2017
- 2017-12-04 CY CY20171101264T patent/CY1119805T1/el unknown
-
2019
- 2019-04-24 CY CY2019021C patent/CY2019021I1/el unknown
- 2019-04-25 LT LTPA2019508C patent/LTPA2019508I1/lt unknown
- 2019-05-03 LU LU00117C patent/LUC00117I2/fr unknown
- 2019-05-06 NL NL300987C patent/NL300987I9/nl unknown
- 2019-05-06 FR FR19C1030C patent/FR19C1030I1/fr active Active
- 2019-05-08 NO NO2019023C patent/NO2019023I1/no unknown
-
2020
- 2020-06-12 US US16/899,848 patent/USRE49741E1/en active Active
-
2021
- 2021-02-17 US US17/177,550 patent/USRE49742E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119805T1 (el) | Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων | |
| Bazeed et al. | Pancreatic cancer: challenges and opportunities in locoregional therapies | |
| Giuliano et al. | Drug-loaded biocompatible nanocarriers embedded in poloxamer 407 hydrogels as therapeutic formulations | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| Alven et al. | Polymer-drug conjugate, a potential therapeutic to combat breast and lung cancer | |
| Fang et al. | Macrophage-targeted hydroxychloroquine nanotherapeutics for rheumatoid arthritis therapy | |
| Chen et al. | Toward the next-generation phyto-nanomedicines: cell-derived nanovesicles (CDNs) for natural product delivery | |
| Sharma et al. | Amalgamated microneedle array bearing ribociclib-loaded transfersomes eradicates breast cancer via CD44 targeting | |
| Cho et al. | 3D printing of poloxamer 407 nanogel discs and their applications in adjuvant ovarian cancer therapy | |
| MX2010002409A (es) | Composiciones y metodos para la distribucion de farmacos escasamente solubles. | |
| Yoo et al. | Overcoming cancer drug resistance with nanoparticle strategies for key protein inhibition | |
| Muluh et al. | Enhancing cancer immunotherapy treatment goals by using nanoparticle delivery system | |
| WO2019155416A3 (en) | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens | |
| MX2013014461A (es) | Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas. | |
| Di Mascolo et al. | μMESH-enabled sustained delivery of molecular and nanoformulated drugs for glioblastoma treatment | |
| Hariharan et al. | Localized drug delivery systems: an update on treatment options for head and neck squamous cell carcinomas | |
| Xie et al. | A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer | |
| CY1121145T1 (el) | Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας | |
| WO2014075203A1 (es) | Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina | |
| Zamanian et al. | Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms | |
| WO2006060325A3 (en) | Coated drug delivery formulations | |
| BRPI0821741B8 (pt) | sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica, método de preparação de composição farmacêutica e seu uso | |
| ATE441402T1 (de) | Verbessertes medizinprodukt | |
| Peng et al. | The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment | |
| Liu et al. | Nanostructured Delivery Systems for Curcumin: Improving Bioavailability and Plaque-Targeting Efficacy in Atherosclerosis |